Vertex Pharmaceuticals Inc. closed $47.49 short of its 52-week high ($510.64), which the company reached on August 1st.

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.65% higher to $462.99 Tuesday, on what proved to be an all-around great ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The biotech stock's price-to-earnings-to-growth (PEG) ratio is a super-low 0.58, according to the London Stock Exchange Group ...

Vertex Pharmaceuticals announced the first accepted medical presentations of the Phase 3 data on the investigational once ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Zacks.com users have recently been watching Vertex (VRTX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Biotechnology company Vertex Pharmaceuticals, Inc. (VRTX) announced Thursday that Health Canada has accepted for review its New Drug ...

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

Vertex Pharmaceuticals Incorporated (VRTX) stock saw a modest uptick, ending the day at $462.99 which represents a slight increase of $2.99 or 0.65% from the prior close of $460. The stock opened at ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 15 years by 6.9% on an annualized basis producing an ...